Weill Cornell Medicine investigators Dr. David Lyden, the Stavros S. Niarchos Professor in Pediatric Cardiology and a professor of pediatrics, and Dr. Ari Melnick, the Gebroe Family Professor of Hematology/Oncology and a professor of medicine, have been awarded Outstanding Investigator Awards from the National Cancer Institute.

Back pain is one of the most common reasons that Americans call in sick to work, with total costs in the United States exceeding $100 billion every year. Spinal disorders such as back pain, neck pain, scoliosis, stenosis, and disc disease are common and can have a severe effect on a person’s overall health in a variety of ways — from impacting a person's ability to enjoy everyday activities and work to disrupting healthy sleep patterns. In recognition of World Spine Day, spine surgeons at the Daniel and Jane Och Spine Hospital at NewYork-Presbyterian offer tips on how to be proactive about spine health.

Stacey Petrower, President, NewYork-Presbyterian Hudson Valley Hospital, is among the 78 women named to the inaugural list of Notable Women in Health Care by Crain’s New York Business.

Dr. Dan Landau, an assistant professor of medicine and of physiology and biophysics at Weill Cornell Medicine and a core member of the New York Genome Center, has received a New Innovator Award from the National Institutes of Health for his research on how tumor cells evolve and acquire new mutations to evade cancer therapies.

At 12:44 a.m. on January 1, NewYork-Presbyterian Brooklyn Methodist Hospital welcomed its New Year’s Baby, Joseph Patrick Bernstein.

The death rate of children whose mothers have died from breast or cervical cancer may be as high as 30 percent in some developing countries, according to a new paper published Nov. 1 in Cancer by Weill Cornell Medicine and NewYork-Presbyterian researchers. This is believed to be the first study to estimate the effect of a mother’s death from cancer on child mortality.

Older adults with cancer are nearly 70 percent more likely to suffer a stroke or heart attack in the year prior to their diagnosis compared with peers without a cancer diagnosis in that same time period, according to new research by Weill Cornell Medicine, NewYork-Presbyterian, and Memorial Sloan Kettering Cancer Center investigators.

In a phase three clinical trial, a drug called sorafenib stopped progression of desmoid tumors for two years in 80 percent of patients who completed treatment, a significant increase in progression-free survival compared with placebo. (Progression-free survival is the length of time a patient lives without worsening of the disease).